Denmark: Patent

The EU Court of Justice faces a pivotal decision on whether medicines approved as monotherapy but labeled for use in combination with other drugs qualify for Supplementary Protection Certificate (SPC) protection as combinations of active ingredients. This referral, stemming from Genmab's attempts to secure SPC protection for loose combinations including daratumumab, could resolve over a decade of legal uncertainty and fundamentally reshape how pharmaceutical companies approach regulatory strategy for combin

Polycystic Ovary Syndrome has been officially renamed Polyendocrine Metabolic Ovarian Syndrome following a 14-year global medical consensus. The new terminology better reflects the condition's complex hormonal, metabolic and reproductive nature, moving beyond the misleading reference to ovarian cysts. What does this fundamental shift in medical understanding mean for patent applications and intellectual property strategy in women's health innovation?

Vi har lavet en kort introduktion til begrebet immaterielle rettigheder. Læs med her.